Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle

被引:87
作者
Doukas, J [1 ]
Blease, K [1 ]
Craig, D [1 ]
Ma, CL [1 ]
Chandler, LA [1 ]
Sosnowski, BA [1 ]
Pierce, GF [1 ]
机构
[1] Select Genet Inc, San Diego, CA 92121 USA
关键词
gene therapy; neovascularization; physiologic; muscles; fibroblast growth factor; platelet-derived growth factor; wounds and injuries; regeneration; wound healing; collagen;
D O I
10.1006/mthe.2002.0579
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Tissue repair is driven by migratory macrophages and fibroblasts that infiltrate injury sites and secrete growth factors. We now report the enhancement of skeletal muscle repair by targeting transgene delivery to these repair cells using matrix-immobilized gene vectors. Plasmid and adenovirus vectors immobilized in collagen-gelatin admixtures were delivered to excisional muscle wounds, and when encoding either fibroblast growth factor-2 (FGF2) or FGF6 transgenes, produced early angiogenic responses that subsequently remodeled into arteriogenesis. FGF2 gene delivery enhanced the number of CD31(+) endothelial cells present at treatment sites >6-fold by day 14, and muscular arteriole density up to 11-fold by day 21 (P < 0.0001). Muscle repair was also enhanced, as FGF gene-treated wounds filled with regenerating myotubes expressing the marker CD56 (an average 20-fold increase in CD56 expression versus controls, P < 0.0001). These responses required transfection of a threshold level of repair cells, achievable only in injured muscles, and were transgene-driven, as neither platelet-derived growth factor-B (PDGFB) gene nor FGF2 protein delivery produced equivalent responses. In conclusion, using biomatrices to direct gene delivery to repair cells allows for relatively complex regenerative processes such as arteriogenesis and myogenesis, and therefore represents a promising approach to treating injured and ischemic muscle.
引用
收藏
页码:517 / 527
页数:11
相关论文
共 50 条
  • [31] EXPRESSION OF RECOMBINANT GENES IN MYOCARDIUM INVIVO AFTER DIRECT INJECTION OF DNA
    LIN, H
    PARMACEK, MS
    MORLE, G
    BOLLING, S
    LEIDEN, JM
    [J]. CIRCULATION, 1990, 82 (06) : 2217 - 2221
  • [32] Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector
    Magovern, CJ
    Mack, CA
    Zhang, J
    Hahn, RT
    Ko, W
    Isom, OW
    Crystal, RG
    Rosengart, TK
    [J]. ANNALS OF THORACIC SURGERY, 1996, 62 (02) : 425 - 433
  • [33] SPECIFIC REGULATION OF N-CAM/D2-CAM CELL-ADHESION MOLECULE DURING SKELETAL-MUSCLE DEVELOPMENT
    MOORE, SE
    WALSH, FS
    [J]. EMBO JOURNAL, 1985, 4 (03) : 623 - 630
  • [34] IN-VIVO ANGIOGENESIS INDUCED BY RECOMBINANT ADENOVIRUS VECTORS CODING EITHER FOR SECRETED OR NONSECRETED FORMS OF ACIDIC FIBROBLAST GROWTH-FACTOR
    MUHLHAUSER, J
    PILI, R
    MERRILL, MJ
    MAEDA, H
    PASSANITI, A
    CRYSTAL, RG
    CAPOGROSSI, MC
    [J]. HUMAN GENE THERAPY, 1995, 6 (11) : 1457 - 1465
  • [35] Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD
    Murry, CE
    Kay, MA
    Bartosek, T
    Hauschka, SD
    Schwartz, SM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (10) : 2209 - 2217
  • [36] Receptor specificity of the fibroblast growth factor family
    Ornitz, DM
    Xu, JS
    Colvin, JS
    McEwen, DG
    MacArthur, CA
    Coulier, F
    Gao, GX
    Goldfarb, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (25) : 15292 - 15297
  • [37] Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor
    Pettersson, A
    Nagy, JA
    Brown, LF
    Sundberg, C
    Morgan, E
    Jungles, S
    Carter, R
    Krieger, JE
    Manseau, EJ
    Harvey, VS
    Eckelhoefer, IA
    Feng, D
    Dvorak, AM
    Mulligan, RC
    Dvorak, HF
    [J]. LABORATORY INVESTIGATION, 2000, 80 (01) : 99 - 115
  • [38] Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
    Rosengart, TK
    Lee, LY
    Patel, SR
    Sanborn, TA
    Parikh, M
    Bergman, GW
    Hachamovitch, R
    Szulc, M
    Kligfield, PD
    Okin, PM
    Hahn, RT
    Devereux, RB
    Post, MR
    Hackett, NR
    Foster, T
    Grasso, TM
    Lesser, ML
    Isom, OW
    Crystal, RG
    [J]. CIRCULATION, 1999, 100 (05) : 468 - 474
  • [39] Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat - Angiogenesis and angioma formation
    Schwarz, ER
    Speakman, MT
    Patterson, M
    Hale, SS
    Isner, JM
    Kedes, LH
    Kloner, RA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (05) : 1323 - 1330
  • [40] Targeting DNA to cells with basic fibroblast growth factor (FGF2)
    Sosnowski, BA
    Gonzalez, AM
    Chandler, LA
    Buechler, YJ
    Pierce, GF
    Baird, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (52) : 33647 - 33653